미국의 OTC 연속 혈당 모니터링 기기 시장 규모, 점유율 및 동향 분석 보고서 : 사용자별, 용도별, 판매 채널별 및 부문별 전망(2026-2033년)

U.S. OTC Continuous Glucose Monitoring (CGM) Devices Market Summary

The U.S. OTC continuous glucose monitoring (CGM) devices market size was valued at USD 194.0 million in 2025 and is projected to grow from USD 207.2 million in 2026 to USD 403.5 million by 2033, at a CAGR of 9.6% from 2026 to 2033. The rising adoption of lifestyle wellness devices, including CGM to ease diabetes management, and easy access to wearable health tools, are fueling demand. In 2025, nearly 20% of Americans planned to use wearable devices to achieve their health goals, while Abbott reported that two out of three U.S. Lingo members began using an OTC CGM to make healthier decisions in real time.

In the coming 5 to 10 years, the adoption rate is expected to reach 50% among elderly Americans. The growing geriatric population and sedentary lifestyles contribute to the disease burden, imposing the development of advanced monitoring solutions such as CGM. Furthermore, expanding healthcare infrastructure and distribution of CGM devices through e-commerce without a prescription would ease accessibility. Technological advancements like sensor accuracy, app integration, and data sharing further support market growth across urban and semi-urban areas.

As of 2025, nearly 38 million American adults are diagnosed with diabetes, marking 11.5% of the total adult population in the U.S. Furthermore, around 97 million adults are prediabetic in the country. Obesity and a sedentary lifestyle are the major contributing factors to the prevalence of diabetes. Continued surge in type 2 diabetes cases and growing awareness of early diagnoses are likely to boost the demand for OTC CGM devices in the U.S.

Newly introduced OTC CGM devices are suggested to be used by type 2 diabetes that are not on insulin. As type 2 diabetes does not get the insurance for prescription CGM, OTC comes in as a help. OTC CGM sells at an affordable rate and without a prescription. Although the OTC CGMs are not covered by insurance, the HAS/FSA funds are generally accepted.

U.S. OTC Continuous Glucose Monitoring (CGM) Devices Market Report Segmentation

This report forecasts revenue growth at the country level and analyzes the latest industry trends and opportunities in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. OTC continuous glucose monitoring (CGM) devices market report based on user, application, and sales channel.

• User Outlook (Revenue, USD Million, 2021 - 2033)
  • Non-diabetic
  • Prediabetic
  • Diabetic
• Application Outlook (Revenue, USD Million, 2021 - 2033)
  • Lifestyle Wellness
  • Diabetes Monitoring
• Sales Channel Outlook (Revenue, USD Million, 2021 - 2033)
  • Company Website
  • Retailers

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Market Definitions
• 1.3. Research Methodology
  • 1.3.1. Information Procurement
  • 1.3.2. Information or Data Analysis
  • 1.3.3. Market Formulation & Data Visualization
  • 1.3.4. Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. U.S. OTC CGM Devices Market Variables, Trends, & Scope

• 3.1. Market Introduction/Lineage Outlook
• 3.2. Market Size and Growth Prospects (USD Million)
• 3.3. Market Dynamics
  • 3.3.1. Market Drivers Analysis
  • 3.3.2. Market Restraints Analysis
• 3.4. U.S. OTC CGM Devices Market Analysis Tools
  • 3.4.1. Porter's Analysis
    • 3.4.1.1. Bargaining power of the suppliers
    • 3.4.1.2. Bargaining power of the buyers
    • 3.4.1.3. Threats of substitution
    • 3.4.1.4. Threats from new entrants
    • 3.4.1.5. Competitive rivalry
  • 3.4.2. PESTEL Analysis
    • 3.4.2.1. Political landscape
    • 3.4.2.2. Economic and Social landscape
    • 3.4.2.3. Technological landscape
    • 3.4.2.4. Environmental landscape
    • 3.4.2.5. Legal landscape

Chapter 4. U.S. OTC CGM Devices Market: User Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. U.S. OTC Continuous Glucose Monitoring (CGM) Devices Market User Movement Analysis
• 4.3. U.S. OTC Continuous Glucose Monitoring (CGM) Devices Market Size & Trend Analysis, by User, 2024 to 2033 (USD Million)
• 4.4. Non-diabetic
  • 4.4.1. Non-diabetic Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.5. Prediabetic
  • 4.5.1. Prediabetic Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.6. Diabetic
  • 4.6.1. Diabetic Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. U.S. OTC CGM Devices Market: Application Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. U.S. OTC Continuous Glucose Monitoring (CGM) Devices Market Application Movement Analysis
• 5.3. U.S. OTC Continuous Glucose Monitoring (CGM) Devices Market Size & Trend Analysis, by Application, 2024 to 2033 (USD Million)
• 5.4. Lifestyle Wellness
  • 5.4.1. Lifestyle wellness market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 5.5. Diabetes Monitoring
  • 5.5.1. Diabetes monitoring market revenue estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 6. U.S. OTC CGM Devices Market: Sales Channel Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. U.S. OTC Continuous Glucose Monitoring Devices Market Sales Channel Movement Analysis
• 6.3. U.S. OTC Continuous Glucose Monitoring Devices Market Size & Trend Analysis, by Sales Channel, 2025 to 2033 (USD Million)
• 6.4. Company Website
  • 6.4.1. Company website Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.5. Retailers
  • 6.5.1. Retailers Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Recent Developments & Impact Analysis by Key Market Participants
• 7.2. Company Categorization
• 7.3. Company Heat Map Analysis
• 7.4. Company Profiles
  • 7.4.1. Abbott Laboratories
    • 7.4.1.1. Company overview
    • 7.4.1.2. Financial performance
    • 7.4.1.3. Product benchmarking
    • 7.4.1.4. Strategic initiatives
  • 7.4.2. Dexcom Inc.
    • 7.4.2.1. Company overview
    • 7.4.2.2. Financial performance
    • 7.4.2.3. Product benchmarking
    • 7.4.2.4. Strategic initiatives